The prevalence of medetomidine is rising across the United States, particularly in the Northeast. Read this article to dive into what communities and clinicians need to know about this sedative, or click on the button below for a short introductory piece on medetomidine.
Read More on Medetomidine
Medetomidine in the Drug Supply:
What Communities and Providers Need to Know
By: Timothy J. Wiegand, MD, DFACMT, DFASAM
What is Medetomidine?
Medetomidine is a potent sedative medication used in medical settings for procedures, agitation, and certain withdrawal symptoms.1-2 This drug is most often used in intensive care units (ICUs) and is considered safe when used medically and at standard doses. However, medetomidine is being added to the illicit drug supply, including opioids (particularly fentanyl or heroin) and stimulants, in unpredictable amounts. When mixed with opioids, medetomidine can potentiate (strengthen) their effects; when mixed with cocaine, it can mask the usual signs of stimulant use by reducing heart rate and blood pressure.1-2
Why is Medetomidine Concerning?
Since 2021, the prevalence of medetomidine in the illicit drug supply has been on the rise. In addition to the rapid increase in prevalence (as depicted in Figure 1), medetomidine puts people at an increased risk of fatal overdose and complicates community overdose response efforts. For people exposed to it, medetomidine can also cause more severe withdrawal symptoms compared to opioids alone, which may increase the risk of dependence on substances.
Complications with Overdose Response
When mixed with opioids like fentanyl, medetomidine overdose may appear like an opioid overdose layered with potent sedative effects: Deep sedation, low heart rate (bradycardia), low blood pressure (hypotension), and prolonged unresponsiveness.3-5 This can make people appear less responsive to naloxone even when fentanyl is present, meaning breathing may improve after naloxone, but the person can remain heavily sedated and require close monitoring.
Severe Withdrawals
Its presence in the supply also introduces a new withdrawal syndrome that is distinct from opioid withdrawal.4-5 Instead of the typical symptoms associated with fentanyl or xylazine, medetomidine withdrawal is marked by severe autonomic hyperactivity (fast heart rate [tachycardia], high blood pressure, agitation, tremors, excessive sweating [diaphoresis], and intense nausea or vomiting. In places like Philadelphia and Pittsburgh, this syndrome has led to ICU‑level hospitalizations, with many patients requiring dexmedetomidine infusions for symptom control.
Increased Risk of Dependence
Finally, medetomidine may increase dependence and harm because it creates another drug people can withdraw from, encouraging more frequent use and compounding health risks.4-6 It’s possible that this drug is being intentionally added to the drug supply to potentiate opioids, mask stimulant effects, and drive repeated use. Together, these factors make medetomidine a rapidly emerging adulterant with serious implications for overdose response, withdrawal management, and community health.
Figure 1:
Timeline of Medetomidine Spread1-6
Takeaways for Community Members
-
Medetomidine has been detected across the United States, with the majority of cases reported in the Northeast. 1-8
-
Naloxone still works for the opioid component of an overdose. Always have it on-hand.
-
Medetomidine may cause prolonged sedation even after naloxone.
-
Access to drug checking tools for medetomidine remains limited.
-
Withdrawal can begin 2–24 hours after last use and may require medical care.7
-
If someone experiences severe agitation, high blood pressure, or rapid heart rate after stopping use, they should seek emergency care.
Information for Clinicians & First Responders
Intoxication/Overdose Syndrome
The overdose phenotype resembles opioid toxicity layered with potent alpha‑2 agonism. Patients typically present with sedation, bradycardia, hypotension, and respiratory depression. Naloxone should still be administered because fentanyl is almost always present, but clinicians should expect persistent sedation even after ventilation improves.
The best-described overdose cluster was in Chicago, from May 11th-17th, 2024: 12 confirmed, 26 probable, and 140 suspected cases involving medetomidine mixed with opioids.3 Fentanyl was found in all medetomidine-positive blood or drug samples. The defining clinical features were bradycardia and minimal or partial naloxone response. The Centers for Disease Control and Prevention (CDC) guidance emphasizes prioritizing airway and ventilation rather than escalating naloxone solely because the patient remains unresponsive.3
Withdrawal Syndrome
Withdrawal has emerged as the more distinctive and clinically challenging syndrome. Instead of sedation and bradycardia, patients develop autonomic overactivity—tachycardia, severe hypertension, agitation, tremor, diaphoresis, fluctuating alertness, and severe nausea or vomiting.4-6 Onset is variable, ranging from 2 to 24 hours, and timing does not reliably predict severity.7
A cluster in Philadelphia (September 2024–January 2025) illustrates the severity: 165 hospitalized patients, 91% requiring ICU care and 24% requiring intubation.4 Withdrawal was often refractory to standard fentanyl/xylazine withdrawal treatments but frequently responsive to dexmedetomidine. Pittsburgh reported a similar pattern, and metabolite testing confirmed medetomidine exposure even when parent drug was not detected—meaning a negative routine urine screen does not exclude exposure.
The University at Pittsburgh independently reported a similar pattern during October 2024–March 2025.5 During this period, 23 patients were evaluated clinically, and in the 10 cases with retrospective testing, medetomidine metabolites were found in all 10, even though only 2 had detectable parent medetomidine on routine comprehensive urine testing. That is clinically important because a negative routine screen for parent drug does not exclude medetomidine exposure.
A key clinical signal: Patients who tolerate very large doses of clonidine or dexmedetomidine (up to 2.4 mcg/kg/min in some centers) should raise strong suspicion for medetomidine withdrawal (J. Perrone, personal communication, March 2026).
Current Management Considerations
There is still no evidence-based consensus management protocol, but the strongest public health guidance currently favors early alpha-2 agonist therapy and early treatment of concurrent opioid withdrawal with long-acting opioids, with close monitoring. Philadelphia/Pennsylvania guidance specifically says clonidine is preferred, some patients need additional alpha-2 agonists. Many severe cases still require hospital therapies such as dexmedetomidine infusion.
Takeaways for Clinicians & First Responders
-
Prevalence is rising fast, especially in the Northeast, and in Philadelphia, it appears to have overtaken xylazine in sampled fentanyl.
-
Intoxication looks like fentanyl plus potent alpha-2 agonism, with only partial apparent improvement with naloxone unless ventilation is supported.
-
Withdrawal is the more distinctive syndrome: severe autonomic hyperactivity, often refractory to standard fentanyl/xylazine-withdrawal approaches and frequently requiring ICU-level care and dexmedetomidine-based management. Onset of w/d varies from 2-24 hours.7
Figure 2: Map of Medetomidine Supply in the U.S.8
References
- Midthun, K.M., Amanda, L.A., Mohr, M.S., Browne, T., & Logan, B.K. (2023, December 8). Toxic adulterant alert: Medetomidine/dexmedetomidine. The Center for Forensic Science Research and Education, United States. Retrieved from: https://www.cfsre.org/nps-discovery/public-alerts/toxic-adulterant-alert-medetomidine-dexmedetomidine
- Krotulski, A.J., Shinefeld, J, Moraff, C, Wood, T, Walton, S.E., DeBord, J.S, Denn, M.T., Quinter, A.D., & Logan, B.K. (2024, May). Medetomidine rapidly proliferating across USA — Implicated in recreational opioid drug supply & causing overdose outbreaks. Center for Forensic Science Research and Education, United States. Retrieved from: https://www.cfsre.org/images/content/reports/public_alerts/Public_Alert_Medetomidine_052024.pdf
- Nham, A., Le, J.N., Thomas, S.A., et al. (2025, May 1). Overdoses involving medetomidine mixed with opioids — Chicago, Illinois, May 2024. MMWR Morb Mortal Wkly Rep 2025;74:258–265. DOI: http://dx.doi.org/10.15585/mmwr.mm7415a1
- Huo, S., London, K., Murphy, L., et al. Notes from the field: Suspected medetomidine withdrawal syndrome among fentanyl-exposed patients — Philadelphia, Pennsylvania, September 2024–January 2025. MMWR Morb Mortal Wkly Rep 2025;74:266–268. DOI: http://dx.doi.org/10.15585/mmwr.mm7415a2.
- Ostrowski, S.J., Tamama, K., Trautman, W.J., Stratton, D.L., & Lynch, M.J. Notes from the field: severe medetomidine withdrawal syndrome in patients using illegally manufactured opioids — Pittsburgh, Pennsylvania, October 2024–March 2025. MMWR Morb Mortal Wkly Rep 2025;74:269–271. DOI: http://dx.doi.org/10.15585/mmwr.mm7415a3
- Zhu D, Mitragotri S, Cano M. David T. Zhu. Temporal and spatial patterns of xylazine and medetomidine detected in the DEA’s National Forensic Laboratory Information System (NFLIS) reports. Social Science & Medicine, Volume 384, 2025, 118521. ISSN 0277-9536. https://doi.org/10.1016/j.socscimed.2025.118521.
- Krotulski, A. (2026, March 20). Human pharmacokinetics of fentanyl, xylazine, and medetomidine in patients presenting to the emergency department after non-fatal opioid overdose [Abstract Presentation]. American College of Medical Toxicology’s Annual Scientific Meeting, Boston MA.
- National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 68602, Medetomidine. Retrieved April 15, 2026 from https://pubchem.ncbi.nlm.nih.gov/compound/Medetomidine.
